Research programme: transdermal protein therapeutics - CSL/PhosphagenicsAlternative Names: CSL actives
Latest Information Update: 26 Apr 2012
At a glance
- Originator CSL; Phosphagenics
- Class Proteins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Unspecified
Most Recent Events
- 20 Apr 2012 Early research is ongoing in Australia
- 19 Jun 2009 Early research in Undefined indication in Australia (Transdermal)